Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINITY study in HER2-positive gastric or gastroesophageal cancer with persistent postoperative ctDNA
2023-506662-31-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan, capecitabine, fluorouracil, docetaxel, oxaliplatin and 1 more in gastric cancer (GC), gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: ctDNA clearance rate at 1 year. Planned start Jan 2024; status: authorised.
02
Drugs
trastuzumab deruxtecancapecitabinefluorouracildocetaxeloxaliplatin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-506662-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506662-31-00.